Tratamentul glioblastomului multiform nou diagnosticat, în asociere cu radioterapia şi apoi ca monoterapie.
Tratamentul glioamelor maligne, (glioblastomul multiform sau astrocitomul anaplazic), care au prezentat recurenţă sau progresie după terapia standard.
Se aplică tuturor denumirilor comerciale, formelor farmaceutice şi concentraţiilor corespunzătoare DCI-ului.
________________________________________________________________________________
DCI/DENUMIRE COMERCIALĂ FORMA FARM.
__________________________________________________
CONCENTRAŢIE FIRMA
________________________________________________________________________________
L01AX03 TEMOZOLOMIDUM CAPS. 100 mg
TEMODAL 100 mg 100 mg SP EUROPE
L01AX03 TEMOZOLOMIDUM CAPS. 20 mg
TEMODAL 20 mg 20 mg SP EUROPE
L01AX03 TEMOZOLOMIDUM CAPS. 250 mg
TEMODAL 250 mg 250 mg SP EUROPE
L01AX03 TEMOZOLOMIDUM CAPS. 5 mg
TEMODAL 5 mg 5 mg SP EUROPE
L01AX03 TEMOZOLOMIDUM
TEMODAL 100 mg 100 mg SP EUROPE
L01AX03 TEMOZOLOMIDUM
TEMODAL 20 mg 20 mg SP EUROPE
L01AX03 TEMOZOLOMIDUM
TEMODAL 5 mg 5 mg SP EUROPE
________________________________________________________________________________
______________________________________________________________________________
| 713 |L01AX04| DACARBAZINUM | |
|_______|_______|____________________________________________|_________________|
________________________________________________________________________________
DCI/DENUMIRE COMERCIALĂ FORMA FARM.
__________________________________________________
CONCENTRAŢIE FIRMA
________________________________________________________________________________
L01AX04 DACARBAZINUM LIOF. PT. SOL. PERF. 200 mg
DALTRIZEN(R) 200 mg 200 mg ACTAVIS S.R.L.
________________________________________________________________________________
______________________________________________________________________________
| 714 |L01BA01| METHOTREXATUM | |
|_______|_______|____________________________________________|_________________|
________________________________________________________________________________
DCI/DENUMIRE COMERCIALĂ FORMA FARM.
__________________________________________________
CONCENTRAŢIE FIRMA
________________________________________________________________________________
L01BA01 METHOTREXATUM CONC. PT. SOL. 100 mg/ml
INJ./PERF.
METHOTREXAT "EBEWE" 1000 mg 100 mg/ml EBEWE PHARMA GMBH NFG. KG
METHOTREXAT "EBEWE" 500 mg 100 mg/ml EBEWE PHARMA GMBH NFG. KG
METHOTREXAT "EBEWE" 5000 mg 100 mg/ml EBEWE PHARMA GMBH NFG. KG
L01BA01 METHOTREXATUM SOL. INJ./PERF. 10 mg/ml
METHOTREXAT "EBEWE" 50 mg 10 mg/ml EBEWE PHARMA GMBH NFG. KG
L01BA01 METHOTREXATUM PULB. PT. SOL. 50 mg
INJ./PERF.
ANTIFOLAN(R) 50 mg 50 mg SINDAN SRL
L01BA01 METHOTREXATUM SOL. INJ. 5 mg/ml
METHOTREXAT "EBEWE" 5 mg 5 mg/ml EBEWE PHARMA GMBH NFG. KG
________________________________________________________________________________
______________________________________________________________________________
| 715 |L01BA04| PEMETREXEDUM**** | Protocol: L047C |
|_______|_______|____________________________________________|_________________|
NOTĂ:
Dostları ilə paylaş: | 
